← All trials
NCT05322616
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 21, 2022
- Primary completion
- Apr 30, 2024
- Completion date
- Jul 31, 2024
- First posted
- Apr 12, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Salubris Biotherapeutics IncLead sponsor
- The Cleveland ClinicOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.